AP01-007 Avalyn Pro00115469 A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Avalyn Pharma Inc.
Start Date
June 4, 2024
End Date
March 9, 2029
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Avalyn Pharma Inc.
Start Date
June 4, 2024
End Date
March 9, 2029